Exenatide once weekly for the treatment of type 2 diabetes
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Exenatide is the first glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus (T2DM). Exenatide lowers blood glucose through multiple mechanisms, including enhancement of glucose-dependent insulin secretion, suppression of excess glucagon secretion, reduction of food intake and slowing of gastric emptying. The current formulation of exenatide requires twice-daily dosing (exenatide BID), and an extended-release formulation of exenatide is now in development for use as a once-weekly injection (exenatide QW). The purpose of this report is to review the most current clinical data on the development of exenatide QW for the treatment of T2DM. In clinical trials, exenatide QW significantly improved glycemic control, resulted in patient weight loss, and was well tolerated in patients with T2DM. In a head-to-head clinical trial, exenatide QW caused greater improvements in glycemic control and was better tolerated than exenatide BID. Given the rapidly increasing prevalence of diabetes and obesity worldwide, exenatide QW is a promising development candidate for the treatment of T2DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Once-weekly treatment with EX-LAR (considering the potential beneficial effects of GLP-1R activation on β cells and weight loss associated with many patients) is a promising potential strategy for diabetes prevention. Similarly, once-weekly EX-LAR preparation can be used as an anti-obesity treatment in patients without T2DM or impaired glucose tolerance (118).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [118]
Citations
Cites
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
The Pathobiology of Diabetic Complications
Brownlee, M. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1615 · Cited by 5,339
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Incretins are intestinally derived hormones that are released in response to food intake and have important effects on glucose homeostasis [13] .”
BackgroundKahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 4×
“These studies, performed in T2DM patients, demonstrated that 10 μg of exenatide BID, either as monotherapy or added in combination with a variety of traditional oral therapies (metformin, sulfonylureas, and/or TZDs), was associated with HbA1c reductions of approximately -1% and body-weight reductions averaging -2 to -…”
BackgroundInfluentialGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“GLP-1 is known to enhance glucose-dependent insulin secretion, improve glucose-dependent suppression of inappropriately high glucagon secretion, slow gastric emptying, and reduce food intake [16-18] in humans.”
Background
Research works printed but not linked: 3
- Ratner RE Rosenstock J Boka G. A dose-finding study of the new GLP-1 agonist AVE0010 in type 2 diabetes insufficiently controlled with metformin. Diabetes 2008;57:A129 [Abstract 433-P]
- Balena R Ratner R Berria R et al. Eight weeks of treatment with the long acting human GLP-1 analogue R1583 improves glycemic control and lowers body weight in subjects with type 2 diabetes mellitus (T2DM) treated with metformin: A double-blind placebo-controlled phase 2 study. Diabetes 2008;57:A33 [abstract 108-OR]
- Diabetes Atlas. Third edition©. International Diabetes Foundation 2006
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“56,57 Furthermore, there is a focus on developing GLP-1RAs that can be taken orally without the need for injections.”
Venoms as a platform for human drugs: translating toxins into therapeutics
King, G. F. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.621940 · Cited by 516
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
“Similarly, once-weekly EX-LAR preparation can be used as an anti-obesity treatment in patients without T2DM or impaired glucose tolerance (118).”
BackgroundMadsbad, S., Kielgast, U., Asmar, M., Deacon, C. F., Torekov, S. S., & Holst, J. J. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01357.x · Cited by 202
Metadata
- Authors
- Malone, J., Trautmann, M., Wilhelm, K., Taylor, K., & Kendall, D. M.
- Affiliations
- Eli Lilly (United States) (US)
- Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, CA 92121, USA
- International Diabetes Center, 3800 Park Nicollet Blvd, Minneapolis, MN, 55416, USA
- ORCID
- Kendall, David M
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2009-03
- Volume
- 18
- Issue
- 3
- Pages
- 359-367
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W1975612744
- Cited by
- 55
- References
- 55
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 1 · 2017: 4 · 2016: 3 · 2015: 3 · 2014: 3 · 2013: 6 · 2012: 4
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- exenatide, sustained-release formulation, GLP-1 receptor agonists, type 2 diabetes, glycemic control, weight loss, insulin secretion, glucagon suppression, gastric emptying, drug tolerability
- MeSH terms
- Exenatide, Animals, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Tolerance, Glycated Hemoglobin, Humans, Peptides, Venoms, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exenatide once weekly for the treatment of type 2 diabetes. https://app.cochat.ai/papers/10.1517/13543780902766802
- The paper
- Malone, J., Trautmann, M., Wilhelm, K., Taylor, K., & Kendall, D. M. (2009). Exenatide once weekly for the treatment of type 2 diabetes. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543780902766802
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.